NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Real Estate Services · USD

Rafael Holdings, Inc. (RFL) Stock Analysis

Rafael Holdings, Inc. (RFL) is a Real Estate Services stock listed on NYSE and quoted in US Dollar.

RFL

$2.56

+$0.09 (+3.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RFL with… →

RFL Key Statistics

As of Sep 4, 2026
Trading
Open
$2.49
Previous Close
$2.47
Day's Range
2.49–2.74
52-Week Range
1.12–3.96
Volume
138.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$133.12M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
135.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Revenue (FY)
$637.00K+128.32%
Net Income (FY)
−$34.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.21M
1-Year Return
+76.55%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
211.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RFL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+116.95%
2025−27.48%
2024−9.84%
2023−2.14%
2022−63.33%
2021−78.13%
2020+30.72%
2019+124.97%
2018 (partial year)+61.84%

As of September 4, 2026.

RFL Revenue and Earnings by Fiscal Year

FY ends July
Fiscal yearRevenueNet incomeNet margin
2024$637.00K−$34.41M−5401.9%
2023$279.00K−$1.88M−672.4%
2022$410.00K−$124.66M−30404.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$637.00K$483.00K−$102.63M−$34.41M−5401.9%
2023$279.00K$279.00K−$15.04M−$1.88M−672.4%
2022$410.00K—−$60.48M−$124.66M−30404.4%

Annual figures as reported, in the company's reporting currency. As of July 31, 2024.

RFL Valuation vs Real Estate Services Median

Median of 61 stocks
MetricRFLReal Estate Services medianvs median
P/S ratio135.841.7478.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 61 Real Estate Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Rafael Holdings, Inc. (RFL) carries a market capitalisation of $133.12M. It is classified in the Real Estate Services industry, within the Real Estate sector. Headcount on file is 21.

Over the past 52 weeks the price has ranged from $1.12 to $3.96. The most recent close on file for RFL is $2.56, dated September 4, 2026. That is +$0.09 (+3.64%) against the previous close. The latest close sits 128.57% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $637.00K. Against the prior fiscal year total of $279.00K, that is a change of +128.32%. The same year closed with a net loss of $34.41M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.72.

Across the 3 fiscal years on file, revenue moves from $410.00K in 2022 to $637.00K in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 135.84. On price-to-sales that is 78 times the Real Estate Services median of 1.74. The medians here are taken across 61 Real Estate Services companies that report the metric.

Beta against the wider market is reported at 0.4. Daily returns over the trailing 8 years annualize to a volatility of 75.65%. Over the trailing twelve months the price has returned +76.55%. Across 5 years the annualized return works out at −42.28%.

Growth & Income

No dividend is on file for RFL.

The strongest complete calendar year on file is 2019 at +124.97%; the weakest is 2021 at −78.13%. Of the 7 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +116.95% year to date.

Peer Comparison

Rafael Holdings, Inc. (RFL) operates in the Real Estate Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rafael Holdings, Inc. RFL $133.12M —
CBRE Group, Inc. CBRE $42.81B 33.8
KE Holdings Inc. BEKE $19.76B 28.4
Jones Lang LaSalle Incorporated JLL $16.67B 17.4

The Real Estate Services industry average P/E ratio is 15.3x. Rafael Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Real Estate Services Stocks

CBRE

CBRE Group, Inc.

$42.81B

 BEKE

KE Holdings Inc.

$19.76B

 JLL

Jones Lang LaSalle Incorporated

$16.67B

 CSGP

CoStar Group, Inc.

$12.52B

 COMP

Compass, Inc.

$8.54B

 FSV

FirstService Corporation

$6.29B
View all Real Estate Services stocks →

Popular Real Estate Stocks

WELL

Welltower Inc.

$170.18B

 PLD

Prologis, Inc.

$133.51B

 EQIX

Equinix, Inc.

$102.22B

 AMT

American Tower Corporation

$81.94B

 SPG

Simon Property Group, Inc.

$79.51B
View all Real Estate stocks →

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Visit website →